Tcc denied as not medically necessary by Humana?

Humana's specific coverage criteria for tcc are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Total Contact Casting as Not Medically Necessary — and How to Appeal

Total contact casting (TCC) is the gold-standard offloading device for plantar neuropathic diabetic foot ulcers (DFUs), but Humana routinely denies it as "not medically necessary" when the clinical record does not explicitly document that the patient meets each criterion in Humana's wound-care coverage policy. The insurer may also assert that a removable cast walker or surgical shoe is an equivalent, less costly alternative. Neither position is unappealable.

## Why This Denial Is Appealable

Major vascular surgery, podiatric, and wound-care professional societies have issued strong guidance — independent of any single trial — that a non-removable knee-high offloading device is the preferred treatment for plantar neuropathic DFUs over removable alternatives, precisely because removable devices are frequently taken off during weight-bearing activity, undermining offloading effectiveness. If your chart supports these clinical facts, the denial rests on an incomplete record review, not a legitimate coverage exclusion.

## Federal Appeal Framework

• Internal appeal (Level 1): File within 180 days of the denial. Humana must decide within 30 days (pre-service) or 60 days (post-service).
• Expedited internal appeal: Available if delay would seriously jeopardize health; decision required within 72 hours.
• External review (ACA §2719 / ERISA §503): After exhausting internal appeals — or if Humana takes more than 60 days — you may request independent external review. The reviewer is a board-certified clinician who must apply current clinical evidence, not only Humana's policy. The ~4-month window from denial to external-review deadline runs fast; request external review immediately after an adverse internal decision.

## Documentation to Gather

1. Diagnosis confirmation: ICD-10 codes for the relevant wound type and underlying neuropathy, confirmed in office notes and imaging reports. 2. Wound assessment: Wound grade/classification per a recognized wound-care classification system, documented in the treating clinician's chart — size, depth, exudate level, absence of active infection/osteomyelitis/severe ischemia. 3. Prior offloading history: Dates and outcomes of any removable walkers, half-shoes, or other offloading modalities previously attempted, with documented failure or inadequacy. 4. Prescriber medical-necessity letter: A wound-care-credentialed provider (DPM, vascular surgeon, CWS/CWSP) explaining why TCC is clinically superior for this patient, citing the specific wound characteristics that make removable alternatives inadequate. 5. Provider credentials: Documentation that the applying provider holds appropriate wound-care credentialing for TCC application (CPT 29445).

## Criteria-Mapping Structure

Pull the exact criteria from Humana's published wound-care medical coverage policy and the FDA-cleared device labeling. For each criterion, list the corresponding chart fact:

| Policy Requirement | Supporting Chart Documentation | |---|---| | Wound type and grade per policy | Office note date + classification per chart | | Absence of active infection | Wound culture results + clinical exam | | Absence of severe peripheral arterial disease | ABI / vascular study report | | Trained/credentialed provider | Provider credential certificate | | Prior offloading modality inadequacy | Dates + outcome notes for prior attempts |

Attach all supporting documentation to the appeal letter. Request a peer-to-peer review between Humana's reviewing clinician and your treating provider before final adverse determination — Humana is required to make a qualified clinician available.